U.S. FDA approves Inluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
New Phase 3b data on Lilly's Taltz and Zepbound used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Syntholene Engages Imperial College of London Expert for Independent Technical Review of Operating Data from Iceland Demonstration Facility
QIMC Ties New Salem-Apple River Helium Zones to a Buried Basement Structure: Gravity, Magnetics and Geochemistry Converge on a Single Fault-Bounded Ramp
